← Eichor
Study identifier: NCT06118723 Synced from ClinicalTrials.gov · July 27, 2026
● Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

Condition: Glioblastoma · High-grade Glioma · Glioblastoma, IDH-wildtype  ·  Sponsor: Jasper Gerritsen

PhaseN/A
Planned participants784
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). Therefore, this study evaluates the efficacy and safety of SMR with and without mapping techniques in HGG patients in terms of survival, functional, neurological, cognitive, and quality of life outcomes. Furthermore, it evaluates which patients benefit the most from SMR, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be operated with supramaximal resection or maximal resection at a 1:3 ratio. Primary endpoints are: 1) overall survival and 2) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months postoperatively. Secondary endpoints are 1) residual CE and NCE tumor volume on postoperative T1-contrast and FLAIR MRI scans 2) progression-free survival; 3) onco-functional outcome, and 4) quality of life at 6 weeks, 3 months, and 6 months postoperatively. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).

This description comes directly from the study's public registry record.

Talk to the study team

Jasper Gerritsen, MD PhD  ·  +31107036130  ·  j.gerritsen@erasmusmc.nl

Arnaud Vincent, MD PhD  ·  +31107034211  ·  a.vincent@erasmusmc.nl

Always discuss trial participation with your own doctor first.

Locations (8)

University of California, San Francisco (UCSF)San Francisco, California, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
University Hospitals LeuvenLeuven, BelgiumRecruiting
Universitätsklinikum HeidelbergHeidelberg, Baden-Wurttemberg, GermanyRecruiting
Technical University MunichMunich, Bavaria, GermanyNot Yet Recruiting
Erasmus Medical CenterRotterdam, South Holland, NetherlandsRecruiting
Haaglanden Medical CentreThe Hague, South Holland, NetherlandsRecruiting
Inselspital Universitätsspital BernBern, SwitzerlandNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06118723